CommNets Members’ Past Publications

Click here for: Chan D.L., Ferone D., Albertelli M., Segelov E., Singh S. (2017). Escalated dose somatostatin analogues (SSAs) in management of neuroendocrine tumours (NETs): A systematic Review. Journal of Clinical Oncology, doi: doi/abs/10.1200/JCO.2017.35.4_suppl.422.

Click here for: Yao J.C., Fazio N., Singh S., Buzzoni, R., Carnaghi C., Wolin E., Tomasek J., Raderer M., Lahner H., Voi M., Bubuteishvili Pacaud L., Rouyrre N., Sachs C., Valle J.W., Delle Fave G., Can Cutsem E., Tesselaar M., Shimada Y., Oh D., Strosberg J., Kulke M.H., Pavel M.E. (2016). Everolimus for advanced, nonfunctional neuroendocrine tumours of the gastrointestinal tract: Efficacy (RADIANT-4) a randomized, placebo-controlled phase 3 study. The Lancet, doi: https://doi.org/10.1016/S0140-6736(15)00817-X.

Click here for: Singh S., Pavel M.E., Strosberg J.R., Bubuteishvili-Pacaud L., Degtyarev E., Neary M., Hunger M., Eriksson J., Fazio N., Kulke M.H., Yao J.C. (2016). Association of disease progression, health related quality of life (HRQoL), and utility in patients (pts) with advanced, nonfunctional, well-differentiated gastrointestinal (GI) or lung neuroendocrine tumours (NET) in the phase 3 RADIANT-4 trial. Journal of Clinical Oncology, doi: 10.1200/JCO.2016.34.15_suppl.4093.

Click here for: “Dual Somatostatin Receptor/FDG PET/CT Imaging in Metastatic Neuroendocrine Tumours: Proposal for a Novel Grading Scheme with Prognostic Significance.” Theranostics 7(5): 1149-1158.

Click here for: Chan, D. L. H., et al. (2017). “Prognostic and predictive biomarkers in neuroendocrine tumours.” Crit Rev Oncol Hematol 113: 268-282.

 

Share